Zimmer Biomet — Feb 6, 2025 release

  Page 4 of 24   Financial Guidance The Company is providing the following full-year 2025 financial guidance: Projected Year Ending December 31, 2025 2025 Reported Revenue Change 1.0% - 3.5% Foreign Currency Exchange Impact (2.0)% - (1.5)% 2025 Constant Currency Revenue Change 3.0% - 5.0% Adjusted Diluted EPS (1) $8.15 - $8.35   (1) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.   Conference Call The Company will conduct its fourth quarter and full-year 2024 investor conference call today, February 6, 2025, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products